outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
[223] Parving HH, Lehnert H, Bröckner-Mortensen J, Gonis R, Andersen S, Arner P, for the Irbesartan in patients with type 2 diabetes and microalbuminura study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8
[224] Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Rinz E, Atkins RC, Rohde R, Raz J, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
[225] Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study investigators. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
[226] Mattock MB, Keen H, Viberti GC, El-Gohari MR, Murrels TJ, Scott GS, Wing JR, Jackson PJ. Coronary heart disease and urinary albumin excretion rate in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1988; 31: 82-7.
[227] Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation endproducts contributes to the dyslipidaemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-5.
[228] American Diabetes Association. Aspirin therapy in Diabetes. Diabetes Care 2000; 23 (suppl 1): S61-62.
[229] Solomon R, Werner C, Mann DJ, DeSilva P. Effects of saline, mannitol, and fluid to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-20.
[230] Smets YFC, Westendorp RGJ, Pijl JW van der, deCharro FT, Ringers J, de Fijter JW, Lemkes HHPJ. Effect of simultaneous pancreas kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet 1999; 353: 1915-9.
[231] Lundbaek K. Introduction: Blood vessel disease in diabetes. In: Lundbaek K, Keen H, editors. Blood vessel disease in diabetes mellitus (V. Capri conference). Acta Diab Lat 1971; 8 (suppl l): 3-4.
[232] Jarrett RJ. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, International textbook of diabetes mellitus. Chichester: John Wiley & Sons: 1992:1459-70.
[233] The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers. Diabetologia 1985; 28 (suppl): 615-40.
[234] Klein R. Hyperglycemia and microvascular and macro-vascular disaease in diabetes. Diabetes Care 1995; 18: 258-68.
[235] Selby JV, Zhang D. Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care 1995; 18: 509-16.
[236] Kannel WB. Prevalence, incidence, and mortality of coronary heart disease. In: Fuster V, Voss R, Topol EJ, editors. Atherosclerosis and coronary artery disease, vol 1, Philadelphia, Pa: Lippincott-Raven; 1996: 13-21.
[237] Bell ET. A post mortem study of vascular disease in diabetes. Arch Pathol 1952; 53: 444-62.
[238] Waller BF, Palumbo PJ, Lie T, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Am J Med 1980; 69: 498-506.
[239] Green A, Hougaard P. Epidemiological studies of diabetes mellitus in Denmark, V. Mortality and causes of death among insulin-treated diabetic patients. Diabetologia 1984; 26: 190-4.
[240] Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care 1992; 15: 1141-55.
[241] Chan P, Pan WH. Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diabetic Med 1995; 12: 504-7.
[242] LÖwell H, Stieber J, Koenig W, Thorad B, HÖrmann A, Gostomzyk J. Das diabetes-bedingte Herzinfarktrisiko in einer süddeutschen BevÖlkerung: Ergebnisse der MONICA-Augs-burg-Studien 1985-1994. Diabetes Stoffw 1999; 8: 11-21.
[243] Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. Framingham Study. Diabetes 1989; 38: 504-9.
[244] Diabetes Epidemiology Research International Mortality Study Croup. Major cross-country differences in risk of dying for people with IDDM. Diabetes Care 1991; 14: 40-54.
[245] Songer TJ, DeBerry K, LaPorte RE, Tuomilehto J. International comparisons of IDDM mortality. Diabetes Care 1992; 15 (suppl 1): 15-21.
[246] Rendel M, Kimmell DB, Bamisedun O, Fulmer J. The health care status of the diabetic population as reflected by physician claims to a major insurer. Arch Intern Med 1993; 153: 1360-6.
[247] Manson JH, Colditz GA, Stampfer MJ, Willet WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-7.
[248] Moss SE, Klein R, Klein BE. Cause specific mortality in a population-based study of diabetes. Am J Publ Health 1991; 81: 1158-62.
[249] Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, the D1S Group: Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996; 39: 1577-83.
[250] Standi E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R. Predictors of 10 year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540-5.
[251] Turner RC, Millns J, Neil HAW, Stratton IM, Mauley SF, Matthews DR, Holman RR, for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998; 316: 823-8.
[252] Kwaan HC. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992; 41 (suppl 2): 32-5.
[253] Vague P, Raccah D, Yuhan Vague I. Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis. Metabolism 1992; 41: 2-6.
[254] Colwell JA, Vascular thrombosis in type II diabetes mellitus. Diabetes 1993; 42: 8-11.
[255] Carter AM, Grant PJ. Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 423-32.
[256] Ceriello A, Giuliano D, Quatraro A, Marchi F, Barbanti M, Lefebvre P. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 1990; 33: 163-7.
[257] Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-25.
[258] Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor-1 in treated type II diabetes and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene. Diabetes 1995; 44: 37-42.
[259] Tschöpe D, Rösen P, Esser J, Schwippert B, Nieuvenhuis HK, Kehrel B, Gries FA. Large platelets circulation in an activated state in diabetes mellitus. Semin Thrombos Hemost 1991; 17: 433-8.
[260] Tschöpe D, Rösen D, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Sem Thromb Hemostas 1993; 19: 122-8.
[261]
